Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Liraglutide vs Retatrutide

Q: What is the difference between Liraglutide and Retatrutide?

Liraglutide is a GLP-1 compound (Subcutaneous route) - Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Retatrutide is a GLP-1 compound (Subcutaneous route) - Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only.

Q: Which has a longer half-life, Liraglutide or Retatrutide?

Retatrutide has the longest published plasma half-life (~6.0 days (144 h)), compared with Liraglutide (13 h).

Q: How often is each compound dosed in the research literature?

Liraglutide: once daily at a published dose range of 0.6–3 mg; Retatrutide: once weekly at a published dose range of 2–12 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Liraglutide and Retatrutide for research use?

Yes - Retatrutide is available from New-U Research Compounds as lab-verified (>99% HPLC) compound.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

LIRAGLUTIDE

Liraglutide

GLP-1

GLP-1R

GLP1-RC-RT

Retatrutide

Triple receptor agonist

GLP-1R · GIPR · GCGR

Key research differences

Liraglutide Retatrutide Receptor profile GLP-1R GLP-1R · GIPR · GCGR Development status Approved therapeutic molecule Investigational Published half-life 13 h ~6.0 days (144 h) Research distinction Shorter-acting GLP-1R agonism Adds glucagon receptor agonism

Published research parameters

Liraglutide Saxenda, Victoza Retatrutide LY3437943 View Retatrutide → Receptor profile GLP-1R GLP-1R · GIPR · GCGR Class GLP-1 Triple receptor agonist Plasma half-life 13 h ~6.0 days (144 h) Time to Cmax 11 h 36 h Development status Approved therapeutic molecule Investigational Study context Regulatory label PK Peer-reviewed human PK Primary publications FDA Saxenda USPI — half-life ~13 h (2023) Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023) Summary Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only.

View published study parameters

Liraglutide Saxenda, Victoza Retatrutide LY3437943 View Retatrutide → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once weekly Published dose range 0.6–3 mg 2–12 mg Published study regimen 0.6 → 1.2 → 1.8 → 2.4 → 3 mg 2 → 4 → 6 → 8 → 12 mg

Source references

FDA Saxenda USPI — half-life ~13 h

FDA prescribing information · 2023

FDA Saxenda USPI — half-life ~13 h (2023)

Pi-Sunyer X et al.

New England Journal of Medicine · 2015

Pi-Sunyer X et al., NEJM 373:11 (2015)

Jastreboff AM et al.

New England Journal of Medicine · 2023

Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)

Rosenstock J et al.

The Lancet · 2023

Rosenstock J et al., Lancet 402:529 (titration arms) (2023)

Frequently asked questions

What is the difference between Liraglutide and Retatrutide?

Which has a longer half-life, Liraglutide or Retatrutide?

How often is each compound dosed in the research literature?

Can you buy Liraglutide and Retatrutide for research use?

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research